Atara Biotherapeutics Q3 revenue beats estimates

Atara Biotherapeutics

12/11/2025 14:08

Overview

Atara Q3 2025 revenue beats analyst expectations despite a significant year-over-year decline

Company reported a net loss of $4.3 mln for Q3 2025, down from $21.9 mln in 2024

Atara reduced workforce by 29% to focus on strategic priorities

Outlook

Atara expects $40 mln milestone payment upon tab-cel BLA approval

Company projects 2025 operating expenses to decrease by at least 60%

Atara explores strategic alternatives to maximize shareholder value

Result Drivers

TAB-CEL TRANSFER - Completion of tab-cel activities transfer to Pierre Fabre Laboratories, including BLA sponsorship and costs, expected to reduce operating expenses

WORKFORCE REDUCTION - Atara reduced workforce by 29% to focus on strategic priorities, retaining essential employees

CASH FLOW IMPACT - Decrease in cash receipts from Pierre Fabre after 2024 milestones contributed to increased net cash used in operating activities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$3.45 mln
$1.40 mln (3 Analysts)
Q3 EPS
-$0.32
Q3 Net Income
-$4.30 mln
Q3 Operating Income
-$3.57 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $16.50, about 23.9% above its November 11 closing price of $12.56

Press Release: ID:nBw68xF6Ca

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)